[ad_1] – Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in Japan – TOKYO, Feb. 5, […]
Tag: Astellas Pharma Inc.
China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
[ad_1] – China has the highest number of cases and deaths from gastric cancer of any country worldwide1 – – Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker expressed […]
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
[ad_1] TOKYO, Oct. 10, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be […]
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
[ad_1] – New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring – TOKYO, Sept. 18, 2024 /PRNewswire/ — Astellas Pharma Inc. […]
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
[ad_1] – HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy – TOKYO, Aug. 27, 2024 /PRNewswire/ […]
